Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

UBS Warburg Cuts Kos Pharmaceuticals to 'Neutral'

UBS Warburg downgraded Kos Pharmaceuticals (KOSP) to neutral from buy.

Analyst C.J. Sylvester says Kos is fully valued after a recent run-up, and he sees limited near-term stock price appreciation. Sylvester notes Kos is now trading close to his $26 12-month target. He notes patent risk to Niaspan and the decelerating cholesterol market continue to be clouds looming over the stock. He continues to believes, however, that Kos should achieve more than 20% top-line growth over the next three years, and greater than 50% earnings per share growth in 2004.

Sylvester maintains his $26 12-month target. He sees 77 cents 2003 earnings per share, and $1.17 for 2004.

blog comments powered by Disqus